Fasiglifam as a new potential treatment option for patients with type 2 diabetes

Bibliography

• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14
   PubMed Web of Science ®Google Scholar
• Sturm R. Stemming the global obesity epidemic: what can we learn from data about social and economic trends? Public Health 2008;122:739-46
   PubMed Web of Science ®Google Scholar
• Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science 2003;299:853-5
   PubMed Web of Science ®Google Scholar
• Blonde L. Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. Am J Med 2010;123(3 Suppl):S12-18
   Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011;34(Suppl 1):S11-61
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59
   PubMed Web of Science ®Google Scholar
• Global guideline for type 2 diabetes. International Diabetes Federation Clinical Guidelines Task Force. Brussels: international Diabetes Federation, 2005. Available from: http://www.idf.org/guidelines/type-2-diabetes [Last accessed 22 June 2013]
   Google Scholar
• Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; Atlanta, GA: 2011
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
   PubMed Web of Science ®Google Scholar
• Qaseem A, Humphrey LL, Sweet DE, et al. Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2012;156:218-31
   PubMed Web of Science ®Google Scholar
• Arai K, Matoba K, Hirao K, et al. Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients. Endocr J 2010;57:499-507
   PubMed Web of Science ®Google Scholar
• Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176-80
   PubMed Web of Science ®Google Scholar
• Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998;15:297-303
   PubMed Web of Science ®Google Scholar
• Vlckova V, Cornelius V, Kasliwal R, et al. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. Drug Saf 2009;32:409-18
   PubMed Web of Science ®Google Scholar
• Cox DJ, Irvine A, Gonder-Frederick L, et al. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care 1987;10:617-21
   PubMed Web of Science ®Google Scholar
• Cahn A, Raz I. Emerging gliptins for type 2 diabetes. Expert Opin Emerg Drugs 2013;18:245-58
   PubMed Web of Science ®Google Scholar
• Pratley RE. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother 2009;10:503-12
   PubMed Web of Science ®Google Scholar
• Rayasam GV, Tulasi VK, Davis JA, Bansal VS. Fatty acid receptors as new therapeutic targets for diabetes. Expert Opin Ther Targets 2007;11:661-71
   PubMed Web of Science ®Google Scholar
• Bailey CJ. Could FFAR1 assist insulin secretion in type 2 diabetes? Lancet 2012;379:1370-1
   PubMed Web of Science ®Google Scholar
• Ferdaoussi M, Bergeron V, Zarrouki B, et al. G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia 2012;55:2682-92
   PubMed Web of Science ®Google Scholar
• Negoro N, Sasaki S, Mikami S, et al. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Lett 2010;1:290-4
   PubMed Web of Science ®Google Scholar
• Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008;57:2280-7
   PubMed Web of Science ®Google Scholar
• Prentki M, Vischer S, Glennon MC, et al. Malonyl-CoA and long chain acyl-CoA esters as metabolic coupling factors in nutrient-induced insulin secretion. J Biol Chem 1992;267:5802-10
   PubMed Web of Science ®Google Scholar
• Gravena C, Mathias PC, Ashcroft SJ. Acute effects of fatty acids on insulin secretion from rat and human islets of Langerhans. J Endocrinol 2002;173:73-80
   PubMed Web of Science ®Google Scholar
• Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40. Nature 2003;422:173-6
   PubMed Web of Science ®Google Scholar
• Ahrén B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 2009;8:369-85
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Maekawa F, Yada T. Oleic acid interacts with GPR40 to induce Ca2+ signalling in rat islet β-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release. Am J Physiol Endocrinol Metab 2005;289:E670-7
   PubMed Web of Science ®Google Scholar
• Shapiro H, Shachar S, Sekler I, et al. Role of GPR40 in fatty acid action on the β cell line INS-1E. Biochem Biophys Res Commun 2005;335:97-104
   PubMed Web of Science ®Google Scholar
• Nagasumi K, Esaki R, Iwachidow K, et al. Overexpression of GPR40 in pancreatic β-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 2009;58:1067-76
   PubMed Web of Science ®Google Scholar
• Kebede M, Alquier T, Latour MG, et al. The fatty-acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 2008;57:2432-7
   PubMed Web of Science ®Google Scholar
• Steneberg P, Rubins N, Bartoov-Shifman R, et al. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab 2005;1:245-58
   PubMed Web of Science ®Google Scholar
• Gehrmann W, Elsner M, Lenzen S. Role of metabolically generated reactive oxygen species for lipotoxicity in pancreatic β-cells. Diabetes Obes Metab 2010;12(Suppl 2):149-58
   PubMedGoogle Scholar
• Naik H, Vakilynejad M, Wu J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol 2012;52:1007-16
   PubMed Web of Science ®Google Scholar
• Leifke E, Naik H, Wu J, et al. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther 2012;92:29-39
   PubMed Web of Science ®Google Scholar
• Araki T, Hirayama M, Hiroi S, Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab 2012;14:271-8
   PubMed Web of Science ®Google Scholar
• Kaku K, Araki T, Yoshinaka R. Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care 2013;36:245-50
   PubMed Web of Science ®Google Scholar
• Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012;379:1403-11
   PubMed Web of Science ®Google Scholar
• Kaku K. Fasiglifam (TAK-875), a novel GPR40 agonist reduces HbA1c in a 24-week clinical study- Phase III study results. Presented at the 56th Annual Meeting of the Japan Diabetes Society 2013
   Google Scholar
• Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95
   PubMed Web of Science ®Google Scholar
• Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 2000;49:1751-60
   PubMed Web of Science ®Google Scholar